eXmoor Pharma managing director Angela Osborne has been named in BioBeat’s “50 Movers and Shakers” which lists the most influential women in UK healthcare businesses.
Ms. Osborne founded the biopharmaceutical and cell therapy manufacturing consultancy eXmoor Pharma in 2004 and has since grown it into a globally recognized leader in its field that has completed more than 300 projects across 12 countries.
In September 2010 she co-founded the Advanced Therapy Medicinal Products (ATMP) Manufacturing Community, or amc, to build critical mass and facilitate the sharing of expertise in ATMP manufacturing. The amc now boasts 170 fee paying members.
Ms. Osborne is a member of the BioIndustry Association (BIA)’s Cell Therapy Industry Group and Manufacturing Groups’ advisory committees. She has now been named alongside 49 other “outstanding” female healthcare business leaders in the 2018 BioBeat list which aims to emphasise the role of women leading and innovating to ensure new technologies and treatments continue to improve UK research, health and society.
Ms, Osborne commented: “There is amazing work being done by women across the board developing new products and processes and pushing the boundaries of bioscience in ways that will hopefully benefit everyone in years to come.
“My inclusion on this list is really thanks to the hard work and dedication of all our talented team at eXmoor who between them have more than 300 years’ combined experience in gene and cell therapy and biopharmaceuticals.”
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.